Sufficient numbers of anti-tumor T cells is a condition of maximal efficacy of anti-hypoxia-A2-adenosinergic drugs during cancer immunotherapy
- 1 August 2020
- journal article
- research article
- Published by Elsevier in Current Opinion in Pharmacology
- Vol. 53, 98-100
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Lessons from the A2A Adenosine Receptor Antagonist–Enabled Tumor Regression and Survival in Patients with Treatment-Refractory Renal Cell CancerCancer Discovery, 2020
- Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell CancerCancer Discovery, 2020
- CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancerProceedings of the National Academy of Sciences, 2013
- Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptorCancer Immunology, Immunotherapy, 2011
- CD39/ENTPD1 Expression by CD4+Foxp3+ Regulatory T Cells Promotes Hepatic Metastatic Tumor Growth in MiceGastroenterology, 2010
- T regulatory cells: hypoxia-adenosinergic suppression and re-direction of the immune responseTrends in Immunology, 2009
- A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cellsBlood, 2008
- A2A adenosine receptor protects tumors from antitumor T cellsProceedings of the National Academy of Sciences of the United States of America, 2006
- Role of A2a Extracellular Adenosine Receptor-Mediated Signaling in Adenosine-Mediated Inhibition of T-Cell Activation and ExpansionBlood, 1997
- Cyclic AMP-Dependent Protein Kinase as a Part of the Possible Down-regulating Pathway in the Antigen Receptor-Regulated Cytotoxic T Lymphocyte Conjugate Formation and Granule ExocytosisAnnals of the New York Academy of Sciences, 1988